Clinical trials in Chaidari – page 7

174 clinical trials in Chaidari, Greece across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Chaidari at a glance

174

clinical trials

Research sites1

Quick filters

174 trials in Chaidari

Open in trial search

Squamous cell carcinoma of head and neck

Recruiting

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug

Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Bicara Therapeutics Inc.

Contact Research Centre

IgA nephropathy

Recruiting

Study of felzartamab compared to placebo in adults with IgA nephropathy

Registered drug

Study of felzartamab compared to placebo in adults with IgA nephropathy

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Codeine Phosphate
Sponsor:Biogen Idec Research Limited

Contact Research Centre

COVID-19

Recruiting

Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

Investigational

Study of ibuzatrelvir alone or combined with remdesivir in adults with COVID-19 who have severely compromised immune systems

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:Ibuzatrelvir
Sponsor:Pfizer Inc.

Contact Research Centre

Ovarian cancer

Recruiting

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo

Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Transitional cell carcinoma

Recruiting

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo

Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Fungal infection+3

Recruiting

Study of fosmanogepix compared to standard antifungal drugs for treating invasive mold infections in adults

Registered drugNo placebo

Study of fosmanogepix compared to standard antifungal drugs for treating invasive mold infections in adults

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Amphotericin B
Sponsor:Basilea Pharmaceutica International AG Allschwil

Contact Research Centre

Graves' disease

Recruiting

Study on the Effects and Safety of Rilzabrutinib for Adults with Graves' Disease

InvestigationalNo placebo

Study on the Effects and Safety of Rilzabrutinib for Adults with Graves' Disease

InvestigationalNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Rilzabrutinib
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Azacitidine
Sponsor:Janssen Cilag International

Contact Research Centre

Head and neck cancer

Recruiting

Study of NBTXR3 and Cetuximab for Elderly Patients with Advanced Head and Neck Cancer Ineligible for Platinum Chemotherapy

Registered drugNo placebo

Study of NBTXR3 and Cetuximab for Elderly Patients with Advanced Head and Neck Cancer Ineligible for Platinum Chemotherapy

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Cetuximab
Sponsor:Johnson & Johnson Enterprise Innovation Inc.

Contact Research Centre

Ischaemic stroke

Recruiting

Study on JX10 for Improving Outcomes in Patients with Acute Ischemic Stroke

Investigational

Study on JX10 for Improving Outcomes in Patients with Acute Ischemic Stroke

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:JX10
Sponsor:Corxel Pharmaceuticals Co. Ltd.

Contact Research Centre

Respiratory syncytial virus infection

Recruiting

Study on the Safety and Immune Response of rBCG-N-RSV Vaccine Compared to BCG Vaccine in Adults Over 60 with Respiratory Syncytial Virus (RSV) Concerns

Registered drugNo placebo

Study on the Safety and Immune Response of rBCG-N-RSV Vaccine Compared to BCG Vaccine in Adults Over 60 with Respiratory Syncytial Virus (RSV) Concerns

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years · Healthy volunteers
Sponsor:Biothervax SpA

Contact Research Centre

Hormone-refractory prostate cancer+1

Recruiting

Study Comparing Ifinatamab Deruxtecan and Docetaxel for Patients with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drugNo placebo

Study Comparing Ifinatamab Deruxtecan and Docetaxel for Patients with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Codeine Phosphate
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Other cities in Greece

The busiest research cities in the country

All 50 cities in Greece

Clinical research in Chaidari

What the registry says about research in the country

01 Head and Neck Cancer Research

Innovative clinical research focusing on squamous cell carcinoma of the head and neck, exploring combination therapy approaches that integrate immunotherapy with traditional treatments.

Immunotherapy Integration
Combination Treatment Strategies
Post-Surgery Care

The study evaluates the effectiveness of combining nivolumab with standard cisplatin-radiotherapy, aiming to improve disease-free survival rates in patients with resected head and neck cancer.

Back to Greece All countries